Within the subset of these 7 patients, the predominant genetic alterations identified in tissue samples undergoing the transformation to small cell lung cancer (SCLC) were characterized by the presence of TP53 mutations, which were evident in 4 out of the 7 cases, accounting for 57.1% of the cohort. This evidence concerns the gene TP53 and small cell lung carcinoma.